Loading...
•
Dec 31, 2024
Ligand Q4 2024 Earnings Report
Reported strong financial results driven by royalty revenue growth and strategic investments in key programs.
Key Takeaways
Ligand Pharmaceuticals reported a strong fourth quarter and full year 2024, driven by royalty revenue growth and strategic investments. The company is reaffirming its 2025 financial guidance, expecting revenue between $180 million and $200 million and adjusted EPS between $6.00 and $6.25.
Total revenues for Q4 2024 increased by 52% to $42.8 million compared to Q4 2023.
Royalties for Q4 2024 were $34.8 million, a 55% increase compared to the same period in 2023, driven by Qarziba and Filspari sales.
GAAP net loss for Q4 2024 was $31.1 million, or $1.64 per share, compared to net income of $18.2 million, or $1.03 per diluted share, for the same period in 2023.
The company is reaffirming its 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.25.
Revenue by Segment
Forward Guidance
Ligand reaffirmed its 2025 financial guidance introduced at its Investor Day on December 10, 2024.
Positive Outlook
- Royalty revenue ranging from $135 million to $140 million.
- Revenue from sales of Captisol ranging from $35 million to $40 million.
- Contract revenue ranging from $10 million to $20 million.
- Total revenue forecast of $180 million to $200 million.
- Adjusted earnings per diluted share are anticipated to range from approximately $6.00 to $6.25.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...